Company / Return on Equity (ROE)
Whitehawk Therapeutics, Inc. Return on Equity (ROE) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-121.4%
FY2025
5-year range
-121.4% / -38.2%
FY2021-FY2025
Trend
-94.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Whitehawk Therapeutics, Inc. reports negative total equity of -121.4% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-121.4% in FY2025 with a 5-year CAGR of -57.7%.
Declined from -38.2% to -121.4% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -40.7pp
- 5-Year Change
- -57.7pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 94.1% year-over-year.
- Peak return on equity (roe) was recorded in FY2019.
- Lowest return on equity (roe) in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -121.4% | -94.1% |
| FY2024 | -62.5% | -63.6% |
| FY2023 | -38.2% | +52.7% |
| FY2022 | -80.7% | - |
| FY2021 | - | - |
| FY2020 | -63.7% | -259.4% |
| FY2019 | -17.7% | +85.6% |
| FY2018 | -122.7% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026